PharmaResources (Shanghai) Past Earnings Performance
Past criteria checks 0/6
PharmaResources (Shanghai)'s earnings have been declining at an average annual rate of -11.6%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 12.6% per year. PharmaResources (Shanghai)'s return on equity is 0.7%, and it has net margins of 1.3%.
Key information
-11.6%
Earnings growth rate
-18.0%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 12.6% |
| Return on equity | 0.7% |
| Net Margin | 1.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How PharmaResources (Shanghai) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 514 | 7 | 81 | 45 |
| 30 Jun 24 | 518 | 21 | 80 | 41 |
| 31 Mar 24 | 499 | 26 | 78 | 38 |
| 31 Dec 23 | 490 | 38 | 74 | 37 |
| 30 Sep 23 | 514 | 75 | 71 | 39 |
| 30 Jun 23 | 511 | 80 | 70 | 38 |
| 31 Mar 23 | 496 | 72 | 80 | 35 |
| 01 Jan 23 | 479 | 67 | 80 | 33 |
| 30 Sep 22 | 485 | 72 | 79 | 30 |
| 30 Jun 22 | 465 | 72 | 77 | 26 |
| 31 Mar 22 | 458 | 73 | 64 | 22 |
| 01 Jan 22 | 448 | 74 | 64 | 17 |
| 30 Sep 21 | 377 | 48 | 61 | 12 |
| 31 Dec 20 | 283 | 49 | 43 | 12 |
| 31 Dec 19 | 245 | 47 | 37 | 10 |
| 30 Jun 19 | 171 | 30 | 35 | 10 |
| 31 Mar 19 | 149 | 19 | 35 | 9 |
| 31 Dec 18 | 126 | 8 | 35 | 8 |
| 30 Sep 18 | 127 | 10 | 27 | 15 |
| 30 Jun 18 | 127 | 11 | 25 | 16 |
| 31 Mar 18 | 131 | 16 | 30 | 13 |
| 31 Dec 17 | 135 | 20 | 34 | 10 |
| 30 Sep 17 | 131 | 20 | 38 | 5 |
| 30 Jun 17 | 127 | 19 | 41 | 0 |
| 31 Mar 17 | 117 | 16 | 40 | 0 |
| 31 Dec 16 | 107 | 14 | 38 | 0 |
| 30 Sep 16 | 95 | 11 | 36 | 0 |
| 30 Jun 16 | 84 | 9 | 35 | 0 |
| 31 Mar 16 | 80 | 7 | 34 | 0 |
| 01 Jan 16 | 76 | 6 | 32 | 0 |
Quality Earnings: 301230 has a high level of non-cash earnings.
Growing Profit Margin: 301230's current net profit margins (1.3%) are lower than last year (14.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301230's earnings have declined by 11.6% per year over the past 5 years.
Accelerating Growth: 301230's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301230 had negative earnings growth (-90.8%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).
Return on Equity
High ROE: 301230's Return on Equity (0.7%) is considered low.